Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The latent membrane protein 1 (LMP1)-derived peptide-human leukocyte antigen (HLA) class I complex is a peptide-major histocompatibility complex (pMHC) class I assembly presented on the surface of cells infected with Epstein-Barr virus (EBV). LMP1 is a key viral oncogene consistently expressed in EBV-associated malignancies, such as nasopharyngeal carcinoma (NPC), Hodgkin's lymphoma, and post-transplant lymphoproliferative disorders (PTLD). Intracellular processing of LMP1 generates specific antigenic peptides (such as YLLEMLWRL or YLQQNWWTL) that are loaded onto HLA class I molecules (most commonly HLA-A*02:01) and presented on the cell surface. This complex serves as a critical target for the host's adaptive immune system, specifically recognized by the T-cell receptors (TCRs) of CD8+ cytotoxic T lymphocytes (CTLs). In therapeutic development, the LMP1-peptide-HLA class I complex is targeted using novel immunotherapies to treat EBV-positive cancers. These therapies include TCR-engineered T-cell (TCR-T) therapies (such as YT-E001), TCR-like monoclonal antibodies (such as L1), and chimeric antigen receptor (CAR) T-cell therapies designed to recognize the specific pMHC complex. Additionally, adoptive cell therapies utilizing EBV-specific T cells (such as tabelecleucel) exploit this target to selectively eliminate EBV-infected tumor cells. However, targeting this complex faces challenges, including antigen escape through LMP1 sequence mutations or HLA downregulation, and potential safety concerns like cytokine release syndrome or off-target toxicity due to cross-reactivity with self-peptides.
Targeted cell lysis via T-cell receptor (TCR) or chimeric antigen receptor (CAR) binding to the peptide-HLA complex, triggering cytotoxic T-lymphocyte (CTL) activation and immune-mediated destruction of EBV-infected cells.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Latent membrane protein 1-derived peptide-human leukocyte antigen class I complex (LMP1-peptide-HLA class I complex).